WuXi STA launches parenteral formulation manufacturing line at Wuxi
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This product is based on Osmotic Controlled Release Oral Delivery System technology
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The joint venture will help both the parties to further develop the high-margin service business
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
40,000 visitors and representatives of more than 80 countries set to visit the show
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
Subscribe To Our Newsletter & Stay Updated